NCT02880293View on ClinicalTrials.gov

Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 23, 2016

Primary Completion Date

November 20, 2023

Study Completion Date

November 20, 2023

Conditions

Hematologic Malignancy

Interventions

DRUG

melphalan

melphalan (140 mg/m2 IV on day -7)

DRUG

fludarabine

fludarabine (40 mg/m2/d on days -5 through -2)

DRUG

thiotepa

thiotepa (5 mg/kg IV on day -67)

DRUG

Cyclophosphamide

cyclophosphamide (50 mg/kg IV on day +3 and +4)

DRUG

Mesna

DRUG

Mycophenolate Mofetil

(15 mg/kg PO/IV TID)

DRUG

Filgrastim

DRUG

Tacrolimus

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02880293 - Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor | Biotech Hunter | Biotech Hunter